Invesco Biotechnology & Genome ETF
PBE
68 hedge funds and large institutions have $47.5M invested in Invesco Biotechnology & Genome ETF in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 30 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
0% more funds holding
Funds holding: 68 → 68 (0)
58% less capital inflows, than outflows
Capital inflows: $4.16M | Capital outflows: $9.8M
60% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$1.12M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$767K |
| 3 |
Morgan Stanley
New York
|
+$627K |
| 4 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$597K |
| 5 |
YHB Investment Advisors
West Hartford,
Connecticut
|
+$172K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$3.28M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$808K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$750K |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$708K |
| 5 |
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$660K |
PBE Hedge Fund Activity: Q4 2016 in Review
68 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2016, worth a combined $47.5M — down 17% from $56.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PBE positions and 8 closed out — a net gain of 2 holders — while 12 added to existing stakes and 30 trimmed.
The largest buyer was Ladenburg Thalmann Financial Services, adding an estimated $1.12M. The largest seller was Bank of America, cutting an estimated $3.28M.
- 68 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $47.5M of Invesco Biotechnology & Genome ETF stock for Q4 2016, down 17% quarter-over-quarter.
- 10 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2016 and 8 closed out, a net change of +2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2016 was Ladenburg Thalmann Financial Services, an estimated $1.12M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2016 was Bank of America, an estimated $3.28M sold.
Based on aggregated 13F filings for Q4 2016.